In the United States, up to 70 percent of 2.9 million to 3.7 million people with hepatitis C (HCV) are unaware of their infection. Although universal screening might be a cost-effective way to identify infections, prevent morbidity, and reduce transmission, few efforts have been made to determine patient opinions about new approaches to screening.
Phillip O Coffin, of the Division of Allergy and Infectious Diseases at the University of Washington in Seattle, and colleagues, surveyed 200 patients in August 2010 at five outpatient clinics of a major public urban medical center in Seattle, with an 85.8 percent response rate.
The sample was 55.3 percent women, median 47 years of age, 56.3 percent white and 32.7 percent African or African-American; 9.5 percent and 2.5 percent reported testing positive for HCV and HIV, respectively. The vast majority of patients supported universal screening for HCV. When presented with three options for screening, 48 percent preferred universal testing without being informed that they were being tested or provided with negative results, 37 percent preferred testing with the chance to "opt-out" of being tested and without being provided with negative results, and 15 percent preferred testing based on clinician judgment. Results were similar for HIV screening.
The researchers concluded that atients support universal screening for HCV, even if that screening involves testing without prior consent or the routine provision of negative test results. They add that current screening guidelines and procedures should be reconsidered in light of patient priorities. Their research was published in BMC Infectious Diseases.
Reference: Coffin PO, Stevens AM, ScottJD, Stekler JD and Golden MR. Patient acceptance of universal screening for hepatitis C virus infection. BMC Infectious Diseases 2011, 11:160doi:10.1186/1471-2334-11-160
The Sterile Processing Conference Survival Guide: How to Make the Most of Your Next Event
March 25th 2025From expert speakers to cutting-edge tools, sterile processing conferences, like the 2025 HSPA Annual Conference and the SoCal SPA's Spring Conference, offer unmatched opportunities to grow your skills, expand your network, and strengthen your department's infection prevention game.
Redefining Material Compatibility in Sterilization: Insights From AAMI TIR17:2024
March 24th 2025AAMI TIR17:2024 provides updated, evidence-based guidance on material compatibility with sterilization modalities. It offers essential insights for medical device design and ensures safety without compromising functionality.
Unraveling a Candida auris Outbreak: Infection Control Challenges in a Burn ICU
March 19th 2025A Candida auris outbreak in a burn intensive care unit (BICU) in Illinois has highlighted the persistent challenges of infection control in high-risk health care settings. Despite rigorous containment efforts, this multidrug-resistant fungal pathogen continued to spread, underscoring the need for enhanced prevention strategies, environmental monitoring, and genomic surveillance.